In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms

Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in vivo reporting, we show that continuous MEKi with...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Discov
Prif Awduron: Teh, Jessica L.F., Cheng, Phil F., Purwin, Timothy J., Nikbakht, Neda, Patel, Prem, Chervoneva, Inna, Ertel, Adam, Fortina, Paolo M., Kleiber, Ines, HooKim, Kim, Davies, Michael A., Kwong, Lawrence N., Levesque, Mitch P., Dummer, Reinhard, Aplin, Andrew E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858088/
https://ncbi.nlm.nih.gov/pubmed/29496664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-0699
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg